OKLAHOMA CITY – A newly approved National Cancer Institute-funded clinical trial aims to improve survival for head and neck cancer patients whose disease returns after radiation therapy – a setback that affects up to 40% of patients and is often associated with poor outcomes.
For these patients, surgery is currently the standard treatment, typically targeting tumors in the mouth, throat or lymph nodes of the neck. This Phase II trial will examine whether giving chemotherapy, or chemotherapy combined with immunotherapy, before surgery can improve survival compared with surgery alone.
Wednesday, February 4, 2026 @ 1:00 PM - Wednesday, February 4, 2026 @ 2:00 PM
Zoom
Thursday, February 5, 2026 @ 3:00 PM - Thursday, February 5, 2026 @ 4:00 PM
Saturday, February 7, 2026 @ 9:00 AM - Saturday, February 7, 2026 @ 11:00 AM
Microsoft Teams
Thursday, February 12, 2026 @ 3:00 PM - Thursday, February 12, 2026 @ 4:00 PM
Thursday, February 19, 2026 @ 1:00 PM - Thursday, February 19, 2026 @ 3:00 PM
The University of Oklahoma, Oklahoma Memorial Union - Frontier Room
Thursday, February 26, 2026 @ 3:00 PM - Thursday, February 26, 2026 @ 4:00 PM
Wednesday, March 4, 2026 @ 1:00 PM - Wednesday, March 4, 2026 @ 2:00 PM
Tuesday, March 10, 2026 @ 4:00 PM - Tuesday, March 10, 2026 @ 5:00 PM